TrialNature communications2025

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial.

Jingjing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.